Compare Abeona Therapeutics Inc (ABEO) vs Dow Jones Industrial Average ETF (DIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Dow Jones Industrial Average ETF — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while Dow Jones Industrial Average ETF trades at $537.6. Which is the better fit depends on your goals.
| ABEO | DIA | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | — |
52-Week High | $7.45 | $542.79 |
52-Week Low | $4.17 | $444.64 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
DIA (SPDR Dow Jones Industrial Average ETF) trades at $538.46, showing minimal daily movement with a slight 0.1% decline. The technical outlook remains bullish with strong moving average signals, though RSI levels suggest potential overbought conditions. Recent dividend distributions highlight the fund's income-generating capabilities, with upcoming payments scheduled through mid-2026.
The ETF offers diversified exposure to Dow Jones blue-chip stocks amid positive market breadth. Key risks include market volatility and geopolitical tensions affecting broad indices. Analyst sentiment remains constructive given the fund's defensive positioning and institutional inflows into core index heavyweights.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →
